Explore

Trendline Trendline
Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas
Trendline Trendline
Life Sciences Companies Invest in Longevity Research to Extend Healthspan

Life Sciences Companies Invest in Longevity Research to Extend Healthspan

Life Sciences Companies Invest in Longevity Research to Extend Healthspan
Trendline Trendline
FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change

FDA Reverses Stance on Atara and Pierre Fabre's Cell Therapy Following Leadership Change
Trendline Trendline
FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy

FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy

FDA Extends Review Period for Biogen and Eisai's Subcutaneous Alzheimer's Therapy
Trendline Trendline
AI-Powered Behavioral Health Provider Theris Launches with Enhanced Platform

AI-Powered Behavioral Health Provider Theris Launches with Enhanced Platform

AI-Powered Behavioral Health Provider Theris Launches with Enhanced Platform
Trendline Trendline
Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment

Intellia Therapeutics Advances CRISPR Gene Editing with FDA Application for Hereditary Angioedema Treatment
Trendline Trendline
RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging

RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging

RIVANNA Secures FDA Clearance for Accuro XV Ultrasound System, Enhancing Musculoskeletal Imaging
Trendline Trendline
FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline

FDA Delays Decision on Biogen and Eisai's Subcutaneous Alzheimer's Therapy, Impacting Treatment Timeline
Trendline Trendline
Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion

Amylyx Pharmaceuticals Advances Avexitide for Post-Bariatric Hypoglycemia with Phase 3 Trial Completion
Trendline Trendline
Hims Hers Expands Telehealth Services with Novo Nordisk Partnership, Signaling Healthcare Evolution

Hims Hers Expands Telehealth Services with Novo Nordisk Partnership, Signaling Healthcare Evolution

Hims Hers Expands Telehealth Services with Novo Nordisk Partnership, Signaling Healthcare Evolution
Trendline Trendline
Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy

Eisai and Biogen's Subcutaneous Alzheimer's Drug Faces FDA Review Delay, Affecting Market Strategy
Trendline Trendline
Immunai and AstraZeneca Expand Collaboration to Enhance Oncology Drug Development

Immunai and AstraZeneca Expand Collaboration to Enhance Oncology Drug Development

Immunai and AstraZeneca Expand Collaboration to Enhance Oncology Drug Development